Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Rosacea

FDA to Review Investigational Rosacea Treatment Epsolay

Brian Park, PharmD

September 18, 2020

Epsolay is an investigational topical cream that utilizes the Company’s patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules.

General Dermatology

FDA Cracks Down on Websites Illegally Selling Opioids

Brian Park, PharmD

September 16, 2020

The unapproved and misbranded opioids, which include tramadol and oxycodone, are being sold without a prescription.

Acne

Winlevi Cream Approved for Acne Vulgaris

Brian Park, PharmD

September 2, 2020

The first-in-class topical acne treatment targets the androgen receptor.

Practice Management

Abbott’s 15-Minute COVID-19 Antigen Test Gets Emergency Use Authorization

Brian Park, PharmD

September 1, 2020

Results are provided within 15 minutes and can be read directly from the testing card.

Psoriasis

Tapinarof Cream Looks Promising for Plaque Psoriasis

Brian Park, PharmD

August 31, 2020

The double-blind, vehicle-controlled studies (PSOARING 1 and PSOARING 2) assessed the efficacy and safety of tapinarof in 1025 patients aged 18 to 75 years with plaque psoriasis.

Practice Management

HHS Authorizes Pharmacists to Administer Vaccines to Children

Brian Park, PharmD

August 31, 2020

HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.

Practice Management

Trial Evaluating Half-Life Extended Monoclonal Antibodies for COVID-19 Begins

Brian Park, PharmD

August 28, 2020

The trial will include up to 48 healthy participants in the UK.

Skin Cancer

FDA: Small Risk of Skin Cancer With Hydrochlorothiazide Use

Brian Park, PharmD

August 27, 2020

Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.